2137 — Brii Biosciences Share News
0.000.00%
Last trade - 00:00- HK$645.88m
- -HK$1.49bn
- CNY18.61m
China's Brii jumps most in near 8 months on commercial launch of COVID therapy
Brief: Brii Biosciences Announces Commercial Launch Of Long-Acting Covid-19 Neutralizing Antibody Therapy In China
Brief: Brii Biosciences Updates On Development Of VIR-3434
Brief: Brii Biosciences Exercises Option For Vir Biotechnology's VIR-3434
Brief: Brii Biosciences Announces Positive Data From Study Of Co's COVID-19 Neutralizing Antibody Therapy
Brief: 6 Dimensions' Long Position In Brii Biosciences Falls To 8.99% - HKEx Filing
Brief: Brii Biosciences Will Be Included In Msci China Small Cap Index As Constituent
Brief: Brii Biosciences Says Co's Amubarvimab/Romlusevimab Combination Therapy Retains Neutralizing Activity Against Omicron Ba.2 Sars-Cov-2 Subvariant
Brief: Brii Bio Announces Positive Data Demonstrating Its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant
China relies on traditional medicine to fight COVID surge in Shanghai
China Kintor's COVID drug candidate cuts hospital, death risk in trial
Brief: Sinopharm Group Reaches Strategic Cooperation With TSB Therapeutics (Beijing)
China's Brii jumps most in 4-1/2 months on COVID therapy tie-up with Sinopharm
Brief: Brii Biosciences Ltd Says Tsb Therapeutics (Beijing) Is Partnering With Sinopharm Holding
Brief: Brii Biosciences Says FY Other Income Was Rmb99.0 Mln Up 17.0%
Media: Hong Kong-listed Brii expects to launch COVID-19 drug as early as January - SCMP
China's Brii Biosciences drops as U.S. FDA puts clinical study on hold
China's Brii says its COVID-19 antibody cocktail retains activity against Omicron
Brief: Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant